Aisling Capital, a NYC-based late-stage life sciences investment firm that partners with companies to bring novel medical therapies to market, closed its newest fund, at $280m.
The new fund will allow Aisling Capital to continue to back clinical stage ventures in order improve global health by rapidly bringing breakthrough medical treatments to market.
Led by managing partners Steve Elms and Andrew Schiff, M.D., Aisling Capital will assist companies developing therapeutics to complete their clinical studies, obtain approval and reach commercialization. Portfolio companies gain access to the firm’s strategic counsel and experience in both financial and medical fields, along with its network that extends from regulatory organizations to pharmaceutical companies and financial institutions.
Aisling Capital is a registered investment advisor with the U.S. Securities and Exchange Commission.